KR20180084983A - 암의 치료를 위한 피리미도-피리미다지논의 용도 - Google Patents

암의 치료를 위한 피리미도-피리미다지논의 용도 Download PDF

Info

Publication number
KR20180084983A
KR20180084983A KR1020187017697A KR20187017697A KR20180084983A KR 20180084983 A KR20180084983 A KR 20180084983A KR 1020187017697 A KR1020187017697 A KR 1020187017697A KR 20187017697 A KR20187017697 A KR 20187017697A KR 20180084983 A KR20180084983 A KR 20180084983A
Authority
KR
South Korea
Prior art keywords
pyrimidazinone
pyrimido
cancer
treatment
Prior art date
Application number
KR1020187017697A
Other languages
English (en)
Inventor
산지바 피. 레디
산딥 굽타
로저 아스트베리 스미스
Original Assignee
아사나 바이오사이언시스 엘엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아사나 바이오사이언시스 엘엘씨 filed Critical 아사나 바이오사이언시스 엘엘씨
Publication of KR20180084983A publication Critical patent/KR20180084983A/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
KR1020187017697A 2015-12-04 2016-11-30 암의 치료를 위한 피리미도-피리미다지논의 용도 KR20180084983A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562263398P 2015-12-04 2015-12-04
US62/263,398 2015-12-04
PCT/US2016/064178 WO2017095898A1 (en) 2015-12-04 2016-11-30 Uses of pyrimido-pyrimidazinones to treat cancer

Publications (1)

Publication Number Publication Date
KR20180084983A true KR20180084983A (ko) 2018-07-25

Family

ID=57570591

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020187017697A KR20180084983A (ko) 2015-12-04 2016-11-30 암의 치료를 위한 피리미도-피리미다지논의 용도

Country Status (15)

Country Link
US (2) US10188654B2 (ko)
EP (1) EP3383399A1 (ko)
JP (1) JP2018535995A (ko)
KR (1) KR20180084983A (ko)
CN (1) CN108601785A (ko)
AR (1) AR106830A1 (ko)
AU (1) AU2016365215A1 (ko)
BR (1) BR112018011196A2 (ko)
CA (1) CA3006762A1 (ko)
IL (1) IL259781A (ko)
MX (1) MX2018006776A (ko)
RU (1) RU2018124289A (ko)
TW (1) TW201726141A (ko)
WO (1) WO2017095898A1 (ko)
ZA (1) ZA201803593B (ko)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3392252B1 (en) * 2011-08-23 2023-10-04 Libertas Bio, Inc. Pyrimido- pyridazinone compounds and use thereof
CN111961035B (zh) * 2019-05-20 2022-11-01 南京科技职业学院 一类含有羟基异喹啉类结构的化合物、药物组合物以及其应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA024109B1 (ru) 2008-04-16 2016-08-31 Портола Фармасьютиклз, Инк. Ингибиторы протеинкиназ
ES2432414T3 (es) * 2008-08-12 2013-12-03 Glaxosmithkline Llc Compuestos químicos
EP2493313B1 (en) 2009-10-29 2017-12-13 Genosco Kinase inhibitors
US8796289B2 (en) * 2011-07-19 2014-08-05 Abbvie Inc. Pyridazino[4,5-D]pyrimidin-5(6H)-one inhibitors of kinases
EP3392252B1 (en) * 2011-08-23 2023-10-04 Libertas Bio, Inc. Pyrimido- pyridazinone compounds and use thereof

Also Published As

Publication number Publication date
JP2018535995A (ja) 2018-12-06
US10188654B2 (en) 2019-01-29
AU2016365215A1 (en) 2018-07-05
MX2018006776A (es) 2018-08-15
BR112018011196A2 (pt) 2018-11-21
EP3383399A1 (en) 2018-10-10
TW201726141A (zh) 2017-08-01
CA3006762A1 (en) 2017-06-08
US20170157126A1 (en) 2017-06-08
CN108601785A (zh) 2018-09-28
IL259781A (en) 2018-07-31
ZA201803593B (en) 2019-04-24
WO2017095898A1 (en) 2017-06-08
AR106830A1 (es) 2018-02-21
RU2018124289A (ru) 2020-01-14
US20190070182A1 (en) 2019-03-07

Similar Documents

Publication Publication Date Title
HK1247202A1 (zh) 用於治療癌症的化合物
DK3288581T3 (da) Fremgangsmåde til behandling af cancer
DK3240801T3 (da) Kombinationstumorimmunterapi
DK3033086T3 (da) Kombinationsterapi til behandling af cancer
IL259996A (en) Combinations for cancer treatment
SI3122358T1 (sl) Kombinacije FGFR- in CMET-inhibitorjev za zdravljenje raka
KR20180084772A (ko) 암 치료를 위한 조합 치료법
DK3148529T3 (da) Forbindelser til behandling af hjernecancer
DK3362066T3 (da) Kombinationsterapi til behandling af maligniteter
DK3458052T3 (da) Kombinationsbehandling af cancer
BR112016022976A2 (pt) Métodos para o tratamento de hcv
DK3393478T3 (da) Kombinationsterapi
DK3374497T3 (da) Modificerede makrofager til anvendelse i behandlingen af kræft
KR102377742B1 (ko) 암치료약
DK3468604T3 (da) Farmaceutiske kombinationer til behandling af cancer
IL263835A (en) Exosome-guided treatment of cancer
DK3302478T3 (da) Pac-1 kombinations behandling
ZA201901578B (en) Combinations including abx196 for the treatment of cancer
DK3407909T3 (da) Cancerbehandling
GB201408297D0 (en) Treatment of cancer
DK3277813T3 (da) Hidtil ukendt terapi
DK3576740T3 (da) Cancerbehandling
KR20180084983A (ko) 암의 치료를 위한 피리미도-피리미다지논의 용도
DK3277325T3 (da) Kombinationsimmunterapi for cancer
IL255167A0 (en) Compounds for the treatment of cancer